Voya Investment Management LLC Purchases 11,464 Shares of RxSight, Inc. $RXST

Voya Investment Management LLC lifted its position in RxSight, Inc. (NASDAQ:RXST) by 73.9% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 26,969 shares of the company’s stock after purchasing an additional 11,464 shares during the quarter. Voya Investment Management LLC’s holdings in RxSight were worth $681,000 at the end of the most recent reporting period.

Several other large investors have also recently made changes to their positions in RXST. ProShare Advisors LLC increased its holdings in shares of RxSight by 50.8% in the fourth quarter. ProShare Advisors LLC now owns 10,229 shares of the company’s stock worth $352,000 after purchasing an additional 3,447 shares during the last quarter. State of Wyoming bought a new stake in shares of RxSight in the fourth quarter worth about $37,000. Tidal Investments LLC bought a new stake in shares of RxSight in the fourth quarter worth about $355,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its holdings in shares of RxSight by 23.5% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 84,958 shares of the company’s stock worth $2,921,000 after purchasing an additional 16,140 shares during the last quarter. Finally, GAMMA Investing LLC grew its position in RxSight by 12,990.8% in the first quarter. GAMMA Investing LLC now owns 8,509 shares of the company’s stock worth $215,000 after acquiring an additional 8,444 shares in the last quarter. 78.78% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several research analysts recently commented on RXST shares. Morgan Stanley lowered RxSight from an “overweight” rating to an “equal weight” rating and dropped their price target for the stock from $20.00 to $9.00 in a research report on Tuesday, July 15th. Wells Fargo & Company lowered RxSight from an “overweight” rating to an “equal weight” rating and dropped their price target for the stock from $25.00 to $9.00 in a research report on Wednesday, July 9th. BTIG Research reiterated a “neutral” rating on shares of RxSight in a research report on Wednesday, July 9th. Bank of America dropped their price target on RxSight from $18.00 to $9.00 and set an “underperform” rating for the company in a research report on Wednesday, July 9th. Finally, Jefferies Financial Group reiterated a “hold” rating and issued a $9.00 price target (down previously from $24.00) on shares of RxSight in a research report on Thursday, July 10th. One research analyst has rated the stock with a Buy rating, nine have issued a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, RxSight has an average rating of “Reduce” and an average price target of $10.00.

RxSight Price Performance

Shares of NASDAQ:RXST opened at $9.06 on Friday. RxSight, Inc. has a 1 year low of $6.32 and a 1 year high of $55.57. The business has a 50 day simple moving average of $8.49 and a two-hundred day simple moving average of $13.41. The firm has a market capitalization of $370.74 million, a PE ratio of -11.33 and a beta of 1.18.

RxSight (NASDAQ:RXST) last announced its earnings results on Thursday, August 7th. The company reported ($0.08) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.04) by ($0.04). RxSight had a negative net margin of 21.93% and a negative return on equity of 11.56%. The business had revenue of $33.64 million for the quarter, compared to analysts’ expectations of $39.78 million. During the same quarter last year, the firm earned ($0.16) EPS. The firm’s quarterly revenue was down 3.7% on a year-over-year basis. Equities research analysts expect that RxSight, Inc. will post -0.7 EPS for the current fiscal year.

RxSight Company Profile

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.